Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 20/20 | 0.75 |
| ▸ | FGFR2 | P21802 | 14/20 | 0.75 |
| ▸ | CSF1R | P07333 | 1/20 | 0.75 |
| ▸ | LYN | P07948 | 1/20 | 0.75 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.75 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.75 |
| ▸ | FLT4 | P35916 | 1/20 | 0.75 |
| ▸ | KDR | P35968 | 1/20 | 0.75 |
| ▸ | BLK | P51451 | 1/20 | 0.75 |
| ▸ | BMX | P51813 | 1/20 | 0.75 |
| ▸ | JAK3 | P52333 | 1/20 | 0.75 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.75 |
| ▸ | TAOK2 | Q9UL54 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16993011 | 0.99 | FGFR1 (0.74) | FGFR1FGFR2CSF1RLYNFGFR4 | |
| SCHEMBL16993159 | 0.95 | FGFR1 (0.74) | FGFR1FGFR2CSF1RLYNFGFR4 | |
| Trifluoroacetic Acid SCHEMBL29545726 | 0.93 | FGFR1 (0.70) | FGFR1FGFR2CSF1RLYNFGFR4 | |
| SCHEMBL18522569 | 0.91 | FGFR1 (0.79) | FGFR1FGFR2CSF1RLYNFGFR4 | |
| SCHEMBL20436300 | 0.90 | FGFR1 (0.77) | FGFR1FGFR2CSF1RLYNFGFR4 | |
| SCHEMBL16993240 | 0.89 | FGFR1 (0.76) | FGFR1FGFR2CSF1RLYNFGFR4 | |
| Hydrochloric Acid SCHEMBL16993187 | 0.89 | FGFR1 (0.75) | FGFR1FGFR2CSF1RLYNFGFR4 | |
| SCHEMBL18522575 | 0.88 | FGFR1 (0.78) | FGFR1FGFR2CSF1RLYNFGFR4 | |
| SCHEMBL28734446 | 0.88 | FGFR1 (0.84) | FGFR1FGFR2CSF1RLYNFGFR4 | |
| SCHEMBL19591943 | 0.88 | FGFR1 (0.84) | FGFR1FGFR2CSF1RLYNFGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210147417-A1 | PROCESSES FOR PREPARING AN FGFR INHIBITOR | PRINCIPIA BIOPHARMA INC. | 2021-05-20 | — | — | US | disclosed |
| US-20200148680-A1 | PROCESSES FOR PREPARING AN FGFR INHIBITOR | PRINCIPIA BIOPHARMA INC. | 2020-05-14 | — | — | US | disclosed |
| WO-2019029541-A1 | FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITOR AND USE THEREOF | 南京药捷安康生物科技有限公司 | 2019-02-14 | — | — | WO | disclosed |
| US-20180215756-A1 | PROCESSES FOR PREPARING AN FGFR INHIBITOR | PRINCIPIA BIOPHARMA, INC. (US) | 2018-08-02 | — | — | US | disclosed |
| US-20180215756-A1 | PROCESSES FOR PREPARING AN FGFR INHIBITOR | PRINCIPIA BIOPHARMA, INC. (US) | 2018-08-02 | — | — | US | disclosed |
| WO-2017027567-A1 | PROCESSES FOR PREPARING AN FGFR INHIBITOR | PRINCIPIA BIOPHARMA, INC. (US) | 2017-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180215756-A1 | PROCESSES FOR PREPARING AN FGFR INHIBITOR | FGFR2, FGFR1, FGFR3 | FGFR1 2/4885FGFR2 1/4885CSF1R 912/4885 |
| US-20210147417-A1 | PROCESSES FOR PREPARING AN FGFR INHIBITOR | FGFR2, FGFR1, FGFR3 | FGFR1 2/4885FGFR2 1/4885CSF1R 912/4885 |
| US-20200148680-A1 | PROCESSES FOR PREPARING AN FGFR INHIBITOR | FGFR2, FGFR1, FGFR3 | FGFR1 2/4885FGFR2 1/4885CSF1R 912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.